Transgene Logo

Transgene

Develops cancer immunotherapies using vaccines and oncolytic viruses.

TNG | PA

Overview

Corporate Details

ISIN(s):
FR0005175080
LEI:
969500PDJW8N0FSGGK69
Country:
France
Address:
400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN

Description

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-09-07 17:45
Inside Information / News release on accounts, results
English 361.9 KB
2022-09-07 17:45
Informations privilégiées / Communiqué sur comptes, résultats
French 373.7 KB
2022-09-07 17:45
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
French 752.4 KB
2022-08-31 17:45
Informations privilégiées / Autres communiqués
French 256.5 KB
2022-08-31 17:45
Inside Information / Other news releases
English 247.2 KB
2022-07-07 18:00
Acquisition or disposal of the issuer's own shares / Information relating to th…
English 174.7 KB
2022-07-07 18:00
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
French 167.1 KB
2022-06-28 08:00
Inside Information / Other news releases
English 271.0 KB
2022-06-28 08:00
Informations privilégiées / Autres communiqués
French 278.5 KB
2022-06-27 08:00
Informations privilégiées / Autres communiqués
French 281.1 KB
2022-06-27 08:00
Inside Information / Other news releases
English 269.9 KB
2022-06-06 08:00
Informations privilégiées / Autres communiqués
French 338.1 KB
2022-06-06 08:00
Inside Information / Other news releases
English 322.9 KB
2022-05-27 08:00
Informations privilégiées / Autres communiqués
French 316.1 KB
2022-05-27 08:00
Inside Information / Other news releases
English 297.0 KB

Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Transgene

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Transgene via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-30 N/A Other Other 30,898,876 32,999,999.57 EUR
2023-05-26 N/A Other Buy 29,325 N/A

Peer Companies

A clinical-stage biotech developing nanomedicines for oncology and diagnostics.
Malaysia
N/A
Metagenomi, Inc. Logo
A genetic medicines company developing therapeutics with a genome editing toolbox.
United States of America
MGX
MindWalk Holdings Corp. Logo
A Bio-Native AI company that integrates AI and lab research for drug discovery.
United States of America
HYFT
Mips Logo
Specializes in helmet-based safety technology to redirect rotational motion.
Sweden
MIPS
A think tank offering research, consulting, and ICT solutions for societal issues.
Japan
3636
Modus Therapeutics Holding AB Logo
Clinical-stage biotech developing a polysaccharide for systemic inflammation.
Sweden
MODTX
Molecure S.A. Logo
Clinical-stage biotech developing small molecule drugs for oncology and fibrotic diseases.
Poland
MOC
Monopar Therapeutics Logo
Clinical-stage biotech developing radiopharmaceuticals for oncology and rare diseases.
United States of America
MNPR
Mural Oncology PLC Logo
Clinical-stage biotech developing novel cytokine-based cancer immunotherapies.
Ireland
MURA
N4 PHARMA PLC Logo
Develops a silica nanoparticle delivery system for nucleic acid-based treatments.
United Kingdom
N4P

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.